Interesting NKTR Put And Call Options For August 2015
at The Street - Wed Dec 24, 2:03PM CST
Investors in Nektar Therapeutics saw new options begin trading this week, for the August 2015 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly...
NKTR: 15.02 (+0.23)
Baxter Seeks FDA Approval of BAX111 to Advance VWD Cure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:00PM CST
Baxter International Inc. (BAX) filed a BLA with the FDA for the approval of BAX 111 - an investigational drug for the treatment of patients with von Willebrand disease (VWD).
ICUI: 83.38 (+1.63), BAX: 74.45 (-0.04), NKTR: 15.02 (+0.23), OSUR: 10.26 (+0.25)
Nektar Therapeutics Has Returned 13.2% Since SmarTrend Recommendation (NKTR)
Comtex SmarTrend(R) - Mon Dec 22, 9:52AM CST
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on October 28th, 2014 at $13.73. In approximately 2 months, Nektar Therapeutics has returned 13.22% as of today's recent price of $15.54.
NKTR: 15.02 (+0.23)
Cancer Pain - Pipeline Review, H1 2014
M2 - Thu Dec 18, 4:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/xthht4/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - AstraZeneca - BioDelivery Sciences International - Nektar Therapeutics - Daiichi Sankyo Company - Egalet Corporation - Aphios Corporation - AcelRx Pharmaceuticals - Nippon Kayaku - Nippon Shinyaku - Orion - Pfizer - Zeria Pharmaceutical - GW Pharmaceuticals - IntelGenx - Benitec Biopharma - Kolon Life Science - Teikoku Seiyaku - BioAlliance Pharma - tesa Labtec - Colby Pharmaceutical - Grunenthal - AngioChem - WEX Pharmaceuticals - Virobay - QRxPharma - Winston Pharmaceuticals - Encore Therapeutics - Afferent Pharmaceuticals - Relevare Pharmaceuticals - Northern Light Pharmaceutical For more information visit http://www.researchandmarkets.com/research/xt...ancer_pain
BDSI: 12.65 (+0.66), ACRX: 6.61 (+0.06), EGLT: 5.97 (+0.21), AMGN: 160.67 (+3.15), NKTR: 15.02 (+0.23)
Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis
PR Newswire - Mon Dec 15, 7:35AM CST
Investor-Edge has initiated coverage on the following equities: Zogenix Inc. (NASDAQ: ZGNX), Eli Lilly and Company (NYSE: LLY), Nektar Therapeutics (NASDAQ: NKTR), Sanofi (NYSE: SNY), and Novartis AG (NYSE: NVS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, December 12, 2014, the NASDAQ Composite ended at 4,653.60, down 1.16%, the Dow Jones Industrial Average lost 1.79%, to finish the day at 17,280.83, and the S&P 500 closed at 2,002.33, down 1.62%. The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 792.98, down 1.63%, while the index has advanced 7.99% in the previous three months. Register for your complimentary reports on these five stocks at:
ZGNX: 1.20 (+0.04), LLY: 70.16 (+0.42), SNY: 46.35 (+0.50), NKTR: 15.02 (+0.23), NVS: 93.91 (+0.66)
Secondary Hyperparathyroidism - Pipeline Review, H2 2014
M2 - Fri Dec 12, 3:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/6x9vld/secondary) has announced the addition of the "Secondary Hyperparathyroidism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Secondary Hyperparathyroidism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Secondary Hyperparathyroidism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Secondary Hyperparathyroidism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen Inc. - Nektar Therapeutics - Astellas Pharma Inc. - Mitsubishi Tanabe Pharma Corporation - OPKO Health, Inc. - NPS Pharmaceuticals, Inc. - Deltanoid Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/6x9vld/secondary
OPK: 9.63 (+0.21), NPSP: 35.06 (+1.18), AMGN: 160.67 (+3.15), NKTR: 15.02 (+0.23)
Nektar Presents Data on Target-Specific Biomarkers from Circulating Tumor Cell Sub-Study of Phase 3 BEACON Study of Etirinotecan Pegol (NKTR-102) in Patients with Advanced Breast Cancer
PR Newswire - Thu Dec 11, 5:00PM CST
Nektar Therapeutics (NASDAQ: NKTR) today presented biomarker data from a sub-study of the Phase 3 BEACON study of etirinotecan pegol (NKTR-102) which collected and analyzed circulating tumor cell (CTC) samples from patients in the study. A total of 80% of the 852 patients enrolled in the BEACON trial participated in the CTC sub-study. Among the 627 patients who participated and had evaluable baseline samples, CTCs were detected in 97% of these samples.
NKTR: 15.02 (+0.23)
Nektar/AstraZeneca's Moventig Gets EU Approval for OIC - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 5:50PM CST
Nektar (NKTR) and AstraZeneca's Moventig gained EU approval for the treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxatives.
BAX: 74.45 (-0.04), AZN: 70.44 (+0.26), SCMP: 13.75 (+0.44), NKTR: 15.02 (+0.23)
Nektar Therapeutics Shares Up 15.9% Since SmarTrend's Buy Recommendation (NKTR)
Comtex SmarTrend(R) - Wed Dec 10, 11:07AM CST
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on October 28th, 2014 at $13.73. In approximately 1 month, Nektar Therapeutics has returned 15.92% as of today's recent price of $15.91.
NKTR: 15.02 (+0.23)
MOVENTIG® Approved In The European Union For Opioid-Induced Constipation
PR Newswire - Tue Dec 09, 7:00AM CST
Nektar Therapeutics (NASDAQ:NKTR) reported partner AstraZeneca today announced that MOVENTIG® (naloxegol) has been granted Marketing Authorisation by the European Commission (EC) for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). MOVENTIG is the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) to be approved in the European Union (EU).
NKTR: 15.02 (+0.23)
Moventig cleared in Europe for OIC
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 6:14AM CST
SGYP: 3.08 (+0.12), PGNX: 6.99 (-0.03), CBST: 100.29 (-0.09), AZN: 70.44 (+0.26), SLXP: 114.92 (-1.18), NKTR: 15.02 (+0.23)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 11:45AM CST
GLOG: 20.40 (-0.98), MILL: 1.23 (-0.07), LPHI: 0.70 (+0.02), NEOT: 6.65 (+0.25), BOBE: 50.58 (-0.04), FES: 1.19 (-0.01), REDF: 2.09 (unch), NKTR: 15.02 (+0.23), PRTO: 10.40 (+0.17), CANF: 3.70 (+0.01), CALI: 1.19 (+0.05), TRT: 2.92 (unch), SQNM: 3.59 (-0.01), CARB: 14.54 (+0.94), SEED: 1.33 (-0.03), BLFS: 1.79 (-0.02), DGLY: 15.62 (+0.82), TCCO: 4.96 (-0.04), ALCO: 49.88 (-0.50), PBYI: 189.96 (+0.12)
Nektar Therapeutics Up 17.2% Since SmarTrend Uptrend Call (NKTR)
Comtex SmarTrend(R) - Wed Dec 03, 9:41AM CST
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on October 28th, 2014 at $13.73. In approximately 1 month, Nektar Therapeutics has returned 17.16% as of today's recent price of $16.08.
NKTR: 15.02 (+0.23)
Migraine - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/xq8n9b/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Migraine - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ache Laboratorios Farmaceuticos - Alder Biopharmaceuticals - Allergan - Amgen - Astellas Pharma - Avanir Pharmaceuticals - BioDelivery Sciences - Biofrontera - Bristol-Myers Squibb - D-Pharm - Eli Lilly and Company - Heptares Therapeutics - Impax Laboratories - IntelGenx - Istituto Italiano di Tecnologia - Medestea Research & Production - Merck & Co - Nektar Therapeutics - Northern Light Pharmaceuticals - Paladin Labs - Pfizer - Pozen - Proreo Pharma - Questcor Pharmaceuticals - Revance Therapeutics - TheraJect - Transcept Pharmaceuticals - Trigemina - Vertex Pharmaceuticals Incorporated - iCeutica For more information visit http://www.researchandmarkets.com/research/xq8n9b/migraine
VRTX: 115.15 (+1.40), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), NKTR: 15.02 (+0.23), AGN: 210.12 (+0.95), IPXL: 31.32 (+0.26), ALDR: 25.67 (+0.43), QCOR: 93.60 (+1.52), MRK: 57.46 (+0.25), TSPT: 1.70 (-0.04), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07)
Allergic Rhinitis - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/w5vk6r/allergic_rhinitis) has announced the addition of the "Allergic Rhinitis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - 3M Drug Delivery Systems - ALK-Abello - Allergopharma Joachim Ganzer - AnaptysBio - Axikin Pharmaceuticals - BioTech - Celsus Therapeutics - ELORAC - Fountain Biopharma - GlaxoSmithKline - GlycoMar Limited - Hisamitsu Pharmaceutical - Johnson & Johnson - KAEL-GemVax - Laboratorios LETI - Ligand Pharmaceuticals - Mitsubishi Tanabe Pharma Corporation - Nektar Therapeutics - NeoPharm - Novartis - Oxagen Limited - Panmira - Protectimmun - Revance Therapeutics - Rottapharm - Shionogi & Co - Stallergenes - Sumitomo Dainippon Pharma - Trimel BioPharma - VentiRx For more information visit http://www.researchandmarkets.com/research/w5...c_rhinitis
JNJ: 104.59 (+0.31), RVNC: 16.65 (+0.42), CLTX: 4.70 (-0.20), GSK: 42.85 (+0.11), NKTR: 15.02 (+0.23), NVS: 93.91 (+0.66)
Baxter Files BLA for BAX 855 in Hemophilia A Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 11:40AM CST
Baxter International Inc (BAX) recently filed a biologics license application (BLA) with the U.S. Food and Drug Administration (FDA) for the approval of BAX 855.
ICUI: 83.38 (+1.63), BAX: 74.45 (-0.04), NKTR: 15.02 (+0.23), OSUR: 10.26 (+0.25)
Baxter Submits Application For US FDA Approval Of BAX 855, Extended Half-Life Recombinant FVIII Based On ADVATE For Hemophilia A
PR Newswire - Mon Dec 01, 8:18AM CST
Nektar Therapeutics (NASDAQ:NKTR) reported that partner Baxter International Inc. today announced that the company has submitted a biologics license application (BLA) to the United States Food and Drug Administration (FDA) for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].
NKTR: 15.02 (+0.23)
Baxter Submits Application for U.S. FDA Approval of BAX 855, Extended Half-Life Recombinant FVIII Based on ADVATE for Hemophilia A
Business Wire - Mon Dec 01, 8:00AM CST
Baxter International Inc. (NYSE:BAX) today announced that the company has submitted a biologics license application (BLA) to the United States Food and Drug Administration (FDA) for the approval of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].
BAX: 74.45 (-0.04), NKTR: 15.02 (+0.23)
Nektar Therapeutics (NKTR): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 7:49AM CST
Nektar Therapeutics might be an intriguing choice for investors as it is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective.
NKTR: 15.02 (+0.23)
Shares of NKTR Up 15.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Nov 26, 9:17AM CST
SmarTrend identified an Uptrend for Nektar Therapeutics (NASDAQ:NKTR) on October 28th, 2014 at $13.73. In approximately 4 weeks, Nektar Therapeutics has returned 15.48% as of today's recent price of $15.85.
NKTR: 15.02 (+0.23)